@FiercePharma: Study stirs new debate over Lantus-cancer link. Article | Follow @FiercePharma
> San Diego-based drugmaker Amylin Pharmaceuticals has laid off about 60 employees, or 4 percent of its workforce, in recent weeks as part of an effort to make the company more efficient, a spokeswoman said. Report
> Britain's health watchdog NICE has rejected Zeltia's drug Yondelis for ovarian cancer, arguing that the Spanish biotech company failed to provide sufficient evidence that it is any better than standard treatment. Report
> Sigma Pharmaceuticals, the Australian drugmaker that posted a record loss last month, appointed a new chairman and said it may miss its full-year profit forecast. Report
> Genzyme (NASDAQ: GENZ) said that Goldman, Sachs & Co. will repurchase $1 billion of Genzyme common stock "under an accelerated stock repurchase program." Report
> Mylan has received FDA approval to make generic versions of Merck's Zocor cholesterol treatment. Release | Report
Biotech News
@FierceBiotech: Expert panel unanimously backs new 'morning after' pill. Report | Follow @FierceBiotech
@JohnCFierce: Boehringer should have folded its flibanserin tent before letting an FDA panel unanimously reject it. Chances of approval: zero. | Follow @JohnCFierce
> FDA experts unanimously reject Boehringer's female libido pill. Story
> CRO braves the public market, files for $100M IPO. News
> BMS writes off Exelixis' lead cancer drug. Report
> GW prices Sativex for MS pain. Story
> Affymax shares plunge on PhIII cardio issues for Hematide. Item
Biotech IT News
> Digital signature standards group lowers fees. Story
> BioClinica unveils BIOP at DIA. News
> FDA continues SPL standard rollout. Item
> Compliance solution firms weigh in on SharePoint. Article
> Drug developers squeeze efficiency from e-clinical investments. Report
> Biopharma cozies up to digital IDs. Story
And Finally... Using gene therapy, researchers developed an experimental cure for Type 1 diabetes in a mouse model. Report